385 results on '"Shvidel, Lev"'
Search Results
2. Primary peg-filgrastim prophylaxis versus filgrastim given “on demand” for neutropenia during therapy with cladribine for hairy cell leukemia
3. Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide and rituximab (FCR) in patients with CLL. A retrospective multicenter 'real-world' study
4. All-Cause Mortality and Its Predictors in Haemato-Oncology Patients with Febrile Neutropenia
5. Vanishing bile duct syndrome in a patient with multiple myeloma treated with bortizomib, lenalidomide and dexamethasone
6. CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia
7. Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma
8. CD74 is a novel transcription regulator
9. Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
10. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter “ Real‐World ” study
11. Increased serum level of alpha-2 macroglobulin and its production by B-lymphocytes in chronic lymphocytic leukemia
12. Can Gilbert's syndrome mitigate chronic lymphocytic leukemia?
13. S-allyl derivatives of 6-mercaptopurine are highly potent drugs against human B-CLL through synergism between 6-mercaptopurine and allicin
14. Efficacy of front‐line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real‐World" study.
15. IL-8 Secreted in a Macrophage Migration-Inhibitory Factor- and CD74-Dependent Manner Regulates B Cell Chronic Lymphocytic Leukemia Survival
16. Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study
17. Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study
18. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome
19. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
20. Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival
21. Thrombotic thrombocytopenic purpura following terbinafine therapy
22. Richterʼs transformation to diffuse large B-cell lymphoma: A retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group
23. Pathogenesis, prevalence, and prognostic significance of cytopenias in chronic lymphocytic leukemia (CLL): a retrospective comparative study of 213 patients from a national CLL database of 1,518 cases
24. Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients
25. Peripheral Blood Cell Mitochondrial Dysfunction in Myelodysplastic Syndrome Can Be Improved by a Combination of Coenzyme Q10 and Carnitine
26. Presenting features and outcome of chronic lymphocytic leukemia patients diagnosed at age 80 years or more. An ICLLSG study
27. Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group
28. Willingness and concerns of transfusion-dependent hematological patients toward the option of home transfusion therapy
29. The Role of Alpha 2 Macroglobulin in IgG-Aggregation and Chronic Activation of the Complement System in Patients With Chronic Lymphocytic Leukemia
30. The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia
31. PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE
32. Significance of bone marrow reticulin fibrosis in chronic lymphocytic leukemia at diagnosis: A study of 176 patients with prognostic implications
33. Insect-bite-like reaction in patients with chronic lymphocytic leukemia: a study from the Israeli Chronic Lymphocytic Leukemia Study Group
34. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival
35. Survival trends among 1,325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel
36. Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group
37. The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants
38. Cell-free IgG-aggregates in plasma of patients with chronic lymphocytic leukemia cause chronic activation of the classical complement pathway
39. Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg
40. The Risk of Bleeding in Patients Receiving Ibrutinib Combined with Novel Direct Oral Anticoagulants
41. The May-Hegglin anomaly
42. Clinical significance of serologic markers related to red blood cell autoantibodies production after red blood cell transfusion—severe autoimmune hemolytic anemia occurring after transfusion and alloimmunization: successful treatment with rituximab
43. Hybrid eosinophilic–basophilic acute myeloid leukaemia diagnosed by electron microscopy
44. Vincristine-Loaded Platelet Infusion for Treatment of Refractory Autoimmune Hemolytic Anemia and Chronic Immune Thrombocytopenia: Rethinking Old Cures
45. Acute basophilic leukaemia: eight unsuspected new cases diagnosed by electron microscopy
46. SHORT COURSE OF BUSULPHAN IN ESSENTIAL THROMBOCYTHAEMIA: REMODELLING OF AN OLD STRATEGY
47. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study
48. Low‐dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD‐FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experience
49. A C5a-Immunoglobulin complex in chronic lymphocytic leukemia patients is associated with decreased complement activity
50. Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.